

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

KOLTERMAN, Orville G. *et al.*

Appl. No.: 10/643,681

Filed: August 18, 2003

For: METHODS FOR REGULATING
GASTROINTESTINAL MOTILITY

Confirmation No.: 4614

Art Unit: 1639

Examiner: LIU, Sue Xu

Atty. Docket: 254/057CON

Communication

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication corrects an inadvertent typographical error in the Response to Final Office Action submitted February 6, 2008, for the above-referenced application. Courtesies extended to Applicant's representative in the telephone conference held February 7, 2008, are gratefully acknowledged. In that telephone conference, the form of this communication was discussed.

In the Response to Final Office Action submitted February 7, 2008, a Terminal Disclaimer was submitted for the instant application and U.S. 7,271,238. However, upon review of the submission, it was discovered that an inadvertent typographical error had been introduced into the Terminal Disclaimer; i.e., the U.S. patent number was incorrectly recited as U.S. 7,281,238 (*emphasis added*).

Accordingly, provided herewith is a Terminal Disclaimer for the instant application and U.S. 7,271,238.

CERTIFICATE OF TRANSMITTAL UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed via EFS-Web at the United States Patent and Trademark Office, on the date shown below.

February 7, 2008
Date of Deposit

Debra Villanueva
Name of Person Mailing Paper
Signature of Person Mailing Paper


Applicants believe that all issues raised in the Final Office Action have been properly addressed in the response submitted February 6, 2008, in view of the present communication. Accordingly, entry of the Terminal Disclaimer provided herewith and reconsideration and allowance of the pending claims are respectfully requested. If the Examiner believes that a telephone interview would serve to facilitate resolution of any outstanding issues, the Examiner is encouraged to contact Applicants' representative at the telephone number below.

No additional fees beyond the statutory fee for a Terminal Disclaimer are believed due for this submission. However, if an additional fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535 referencing Docket No. 254/057CON. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Date: February 7, 2008

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.



Steven C. Koerber
Reg. No. 54,233

Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, California 92121
Phone (858) 754-4121
Facsimile (858) 522-1936